Dr. Grob on the Tolerability and Efficacy of Ipilimumab in Melanoma

Jean Jacques Grob, MD, PhD
Published: Thursday, Aug 24, 2017



Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.

The ratio between tolerability and efficacy depends on the different dosages of ipilimumab in the adjuvant setting, states Grob. Three different dosages are currently being used: 10 mg/kg, 3 mg/kg, and 1mg/kg.

In the adjuvant setting, only 10 mg/kg has been studied so far, but studies are ongoing with all the dosages. The toxicity that has been observed in the adjuvant trial with 10 mg/kg was very high, explains Grob. Despite the very good impact on relapse-free survival and overall survival, there is a big debate—for many reasons—about whether it is reasonable to use the dosage in patients for adjuvant therapy.

SELECTED
LANGUAGE


Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.

The ratio between tolerability and efficacy depends on the different dosages of ipilimumab in the adjuvant setting, states Grob. Three different dosages are currently being used: 10 mg/kg, 3 mg/kg, and 1mg/kg.

In the adjuvant setting, only 10 mg/kg has been studied so far, but studies are ongoing with all the dosages. The toxicity that has been observed in the adjuvant trial with 10 mg/kg was very high, explains Grob. Despite the very good impact on relapse-free survival and overall survival, there is a big debate—for many reasons—about whether it is reasonable to use the dosage in patients for adjuvant therapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x